ATE518845T1 - Optische isomere eines iloperidon-metaboliten - Google Patents

Optische isomere eines iloperidon-metaboliten

Info

Publication number
ATE518845T1
ATE518845T1 AT02767454T AT02767454T ATE518845T1 AT E518845 T1 ATE518845 T1 AT E518845T1 AT 02767454 T AT02767454 T AT 02767454T AT 02767454 T AT02767454 T AT 02767454T AT E518845 T1 ATE518845 T1 AT E518845T1
Authority
AT
Austria
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
AT02767454T
Other languages
German (de)
English (en)
Inventor
Dominique Grimler
Hans Kalkman
Hequn Yin
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE518845T1 publication Critical patent/ATE518845T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT02767454T 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten ATE518845T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
ATE518845T1 true ATE518845T1 (de) 2011-08-15

Family

ID=23228843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767454T ATE518845T1 (de) 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP2305656B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK1425272T3 (enExample)
ES (2) ES2370634T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
EP2029136A4 (en) * 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
JP5586094B2 (ja) 2007-03-29 2014-09-10 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
EP3075865B1 (en) 2007-05-18 2018-05-09 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2222300B1 (en) 2007-12-13 2014-06-11 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
EP2222301B1 (en) 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
CA2757723C (en) 2009-04-06 2018-07-24 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
EP2416779B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
EP3354753B1 (en) 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP2515863A2 (en) 2009-12-23 2012-10-31 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
KR20170008327A (ko) 2012-03-14 2017-01-23 반다 파마슈티칼즈, 인코퍼레이티드. 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
CN116211857A (zh) 2015-02-17 2023-06-06 万达制药公司 用于治疗精神分裂症的伊潘立酮
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
CN113474315B (zh) * 2019-02-21 2022-07-05 深圳艾欣达伟医药科技有限公司 制造高镜像选择性二级醇的方法
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
US20250248985A1 (en) 2022-04-13 2025-08-07 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
AU2023408198A1 (en) 2022-12-19 2025-05-29 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
EP4687899A1 (en) 2023-06-02 2026-02-11 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone
WO2026156184A1 (en) * 2025-01-17 2026-07-23 Vanda Pharmaceuticals Inc. Method of treatment with milsaperidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU735249B2 (en) * 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
DK1425272T3 (da) 2011-11-21
US20090176739A1 (en) 2009-07-09
US20130296366A1 (en) 2013-11-07
ES2370634T3 (es) 2011-12-21
CY1113550T1 (el) 2016-06-22
US7977356B2 (en) 2011-07-12
JP2015214577A (ja) 2015-12-03
CY1112039T1 (el) 2015-11-04
ES2398434T3 (es) 2013-03-19
JP2013227335A (ja) 2013-11-07
HK1156309A1 (en) 2012-09-07
JP2010100633A (ja) 2010-05-06
JP2015227368A (ja) 2015-12-17
DK2305656T3 (da) 2013-02-11
US20110201646A1 (en) 2011-08-18
WO2003020707A1 (en) 2003-03-13
PT2305656E (pt) 2013-01-10
JP2005504783A (ja) 2005-02-17
EP1425272B1 (en) 2011-08-03
EP2305656A1 (en) 2011-04-06
JP2013116905A (ja) 2013-06-13
HK1066536A1 (en) 2005-03-24
ES2398434T8 (es) 2017-10-09
US20050020632A1 (en) 2005-01-27
EP2305656B1 (en) 2012-10-24
EP1425272A1 (en) 2004-06-09
PT1425272E (pt) 2011-10-19
US8314129B2 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
DK1425272T3 (da) Optiske isomerer af en iloperidon-metabolit
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
JP2010519243A5 (enExample)
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
NO20051965D0 (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
DE502004009532D1 (de) Fungizide ternäre wirkstoffkombinationen
NO20062370L (no) Amidderivater
NO341632B1 (no) Ny polymorf form av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid
JP2005504783A5 (enExample)
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
RU2010134361A (ru) Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа
ATE544756T1 (de) Substituierte carbinolverbindungen
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
AR049699A1 (es) Derivados de pirimidina
JP2010143943A5 (enExample)
BRPI0411603A (pt) 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
JP2013510155A5 (enExample)
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
RU2503674C2 (ru) Замещенные производные сульфонамида
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425272

Country of ref document: EP